Search

C19H17BrO3, triclinic, P 1‾ $\overline{1}$ (no. 2), a = 8.2887(7) Å, b = 8.4190(12) Å, c = 13.1164(15) Å, α = 93.634(11)°, β = 90.609(9)°, γ = 118.201(11)°, V = 804.17(18) Å3, Z = 2, R gt(F) = 0.0738, wR ref(F 2) = 0.1614, T = 150 K.

C18H15BrO2, monoclinic, P21/n (no. 14), a = 9.1704(9) Å, b = 16.5309(13) Å, c = 10.3528(12) Å, β = 112.368(12)°, V = 1451.3(3) Å3, Z = 4, R gt(F) = 0.0405, wR ref(F 2) = 0.0677, T = 149.99(10) K.

C26H18F2N2O3S, monoclinic, P21/c (no. 14), a = 8.412(3) Å, b = 22.056(8) Å, c = 12.125(4) Å, β = 102.316(5)°, V = 2198.0(14) Å3, Z = 4, Rgt(F) = 0.0475, wRref(F2) = 0.1156, T = 173(2) K.

In the title compound, [Cu(SO4)(C15H11N5)(H2O)]·CH3OH·2H2O, the CuII ion is in a distorted square-pyramidal geometry, in which three N atoms from the chelating 1-(1,10-phenanthrolin-2-yl)-1H-pyrazol-3-amine ligand and one O atom from a sulfate anion define the basal plane and the O atom from the coordinating water molecule is located at the apex. In the crystal, hydrogen-bonding interactions involving the coordinating and solvent water molecules, the methanol solvent molecule and the amine group (one with an intramolecular interaction to one of the sulfate O atoms) of the complex are observed. π–π interactions between symmetry-related phenantroline moieties, with a shortest centroid–centroid interaction of 3.573 (2)°, are also present.